AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
AGENUS INC (AGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.70% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-03-16
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.70%, a 2.63% decline from fiscal 2024.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.80%, a 15.15% increase from fiscal 2023.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.30%, a 83.33% increase from fiscal 2022.
- AGENUS INC share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.80%, a 125.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|
| 2025-12-31 | 3.70% 10-K · filed 2026-03-16 | |
| 2024-12-31 | 3.80% 10-K · filed 2026-03-16 | |
| 2023-12-31 | 3.30% 10-K · filed 2026-03-16 | |
| 2022-12-31 | 1.80% 10-K · filed 2025-03-17 | |
| 2021-12-31 | 0.80% 10-K · filed 2024-03-14 | |
| 2020-12-31 | 0.80% 10-K · filed 2023-03-16 | |
| 2019-12-31 | 1.80% 10-K · filed 2022-03-01 | |
| 2018-12-31 | 2.80% 10-K · filed 2021-03-16 | |
| 2017-12-31 | 1.70% 10-K · filed 2020-03-16 | |
| 2016-12-31 | 1.00% 10-K · filed 2019-03-18 | |
| 2015-12-31 | 1.60% 10-K · filed 2018-03-16 | |
| 2014-12-31 | 1.70% 10-K · filed 2017-03-16 | 1.74% 10-K · filed 2015-03-16 |
| 2013-12-31 | 1.50% 10-K · filed 2016-03-15 | 1.49% 10-K · filed 2014-03-07 |
| 2012-12-31 | 0.90% 10-K · filed 2015-03-16 | |
| 2011-12-31 | 1.60% 10-K · filed 2014-03-07 | |
| 2010-12-31 | 2.10% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |